- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Researchers Report on Biosimilar Interferon Beta-1A in Treating MS
During the fourth congress of the European Academy of Neurology, held in Lisbon, Portugal, from June 16 to 19, researchers reported on CinnaGen’s biosimilar interferon beta 1A drug, CinnoVex, in treating multiple sclerosis (MS).
During the fourth congress of the European Academy of Neurology, held in Lisbon, Portugal, from June 16 to 19, researchers reported on CinnaGen’s biosimilar interferon beta 1A drug, CinnoVex. The biosimilar, approved in Iran, Russia, Syria, and Armenia, references Avonex and is used in the treatment of multiple sclerosis (MS). The researchers reported on the efficacy and safety of the biosimilar versus its reference in Russian patients with relapsing-remitting MS (RR MS).
The study included 92 patients with RR MS who were treated with the biosimilar, and 59 patients who were treated with the reference. Safety and efficacy were evaluated after 1 year of treatment. For the efficacy assessment, annual relapse rate (ARR), disability progression, and the presence of new lesions visible on MRI assessment were all analyzed. Adverse events (AEs) were analyzed for the safety assessment.
At 1 year, write the authors, there were no significant differences in baseline characteristics between the 2 groups. Reduction in ARR from baseline was similar between the 2 groups; the patients receiving the biosimilar reduced their ARR to 0.36 at 1 year from 0.74 at baseline, and the patients receiving the reference reduced their ARR to 0.38 at 1 year from 0.81 at baseline.
Additionally, 91% of patients receiving the biosimilar and 88% of patients receiving the reference had no disability progression during the treatment period, and 16% and 14% of the patients in the 2 groups, respectively, were free from new lesions.
The most frequently reported AEs in both groups were flu-like symptoms (51% in the biosimilar group and 58% in the reference group) and local reactions (4% in the biosimilar group and 3% in the reference group).
The authors concluded that the results of the study suggest that the biosimilar product has equivalent safety and efficacy to the reference in treating patients with RR MS.
Reference
Devlikamova F, Dykhanov A, Khabirov F, Khaybullin T, Granatov E. Interferon beta-1A biosimilar in patients with relapsing remitting multiple sclerosis. Presented at the European Academy of Neurology Congress, June 16-19, 2018; Lisbon, Portugal. Abstract POD407. https://ipp-ean18.netkey.at/index.php?p=recorddetail&rid=77931c3b-9acc-475c-8cf4-5e2024d0095d&t=browsesessions#ipp-record-d9da5197-df7c-4f04-9181-4e8108a8b93c.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Patient With MS Sues J&J Over ERISA Violation
February 14th 2024After a patient with multiple sclerosis (MS) was forced to pay exorbitant out-of-pocket costs for a brand name medication when she could’ve gotten a generic for way less, the patient filed a class action complaint against her employer, Johnson & Johnson (J&J), for violating the Employee Retirement Income Security Act of 1974 (ERISA).
IQVIA Projects $192 Billion Loss for Originators by 2028 Thanks to Biosimilar, Generic Competition
January 18th 2024The IQVIA Institute for Human Data Science’s most recent Global Use of Medicines report projected that market introductions of new biosimilar and generic drugs will increase projected losses for originator products from $111 billion to $192 billion over the next 5 years.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
EC Approves First MS Biosimilar; Coherus Receives CRL for Neulasta Onpro Competitor
September 27th 2023With the European Commission's (EC) approval of Tyruko, Europe receives its first natalizumab biosimilar and first biosimilar to treat multiple sclerosis (MS), while Coherus Biosciences received a complete response letter (CRL) for its biosimilar for Neulasta Onpro.
